Nyxoah (NASDAQ:NYXH – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.
Insider & Institutional Ownership
58.6% of KORU Medical Systems shares are owned by institutional investors. 20.6% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and price targets for Nyxoah and KORU Medical Systems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 0 | 3 | 0 | 2.50 |
| KORU Medical Systems | 1 | 1 | 3 | 1 | 2.67 |
Profitability
This table compares Nyxoah and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -1,457.97% | -101.99% | -66.74% |
| KORU Medical Systems | -9.49% | -22.43% | -13.86% |
Risk & Volatility
Nyxoah has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Valuation and Earnings
This table compares Nyxoah and KORU Medical Systems”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $4.89 million | 26.12 | -$64.10 million | ($2.49) | -1.51 |
| KORU Medical Systems | $33.65 million | 6.57 | -$6.07 million | ($0.08) | -59.63 |
KORU Medical Systems has higher revenue and earnings than Nyxoah. KORU Medical Systems is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Summary
KORU Medical Systems beats Nyxoah on 10 of the 14 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
